Indole-3-Propionic Acid, a Gut-Derived Tryptophan Metabolite, Associates with Hepatic Fibrosis.
Adult
Bariatric Surgery
Cell Adhesion
/ drug effects
Cell Movement
/ drug effects
Female
Gene Expression
/ drug effects
Hepatic Stellate Cells
/ metabolism
Humans
Indoles
/ blood
Liver
/ cytology
Liver Cirrhosis
/ blood
Male
Middle Aged
Obesity
/ blood
RNA, Messenger
/ metabolism
Transforming Growth Factor beta1
/ metabolism
gut microbiota
hepatic fibrosis
hepatic stellate cells
indole-3-propionic acid
non-alcoholic fatty liver disease
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
05 Oct 2021
05 Oct 2021
Historique:
received:
25
08
2021
revised:
28
09
2021
accepted:
30
09
2021
entrez:
23
10
2021
pubmed:
24
10
2021
medline:
20
11
2021
Statut:
epublish
Résumé
Gut microbiota-derived metabolites play a vital role in maintenance of human health and progression of disorders, including obesity and type 2 diabetes (T2D). Indole-3-propionic acid (IPA), a gut-derived tryptophan metabolite, has been recently shown to be lower in individuals with obesity and T2D. IPA's beneficial effect on liver health has been also explored in rodent and cell models. In this study, we investigated the association of IPA with human liver histology and transcriptomics, and the potential of IPA to reduce hepatic stellate cell activation in vitro. A total of 233 subjects (72% women; age 48.3 ± 9.3 years; BMI 43.1 ± 5.4 kg/m Circulating IPA levels were found to be lower in individuals with liver fibrosis compared to those without fibrosis ( The association of circulating IPA with liver fibrosis and the ability of IPA to reduce activation of LX-2 cells suggests that IPA may have a therapeutic potential. Further molecular studies are needed to investigate the mechanisms how IPA can ameliorate hepatic fibrosis.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Gut microbiota-derived metabolites play a vital role in maintenance of human health and progression of disorders, including obesity and type 2 diabetes (T2D). Indole-3-propionic acid (IPA), a gut-derived tryptophan metabolite, has been recently shown to be lower in individuals with obesity and T2D. IPA's beneficial effect on liver health has been also explored in rodent and cell models. In this study, we investigated the association of IPA with human liver histology and transcriptomics, and the potential of IPA to reduce hepatic stellate cell activation in vitro.
METHODS
METHODS
A total of 233 subjects (72% women; age 48.3 ± 9.3 years; BMI 43.1 ± 5.4 kg/m
RESULTS
RESULTS
Circulating IPA levels were found to be lower in individuals with liver fibrosis compared to those without fibrosis (
CONCLUSION
CONCLUSIONS
The association of circulating IPA with liver fibrosis and the ability of IPA to reduce activation of LX-2 cells suggests that IPA may have a therapeutic potential. Further molecular studies are needed to investigate the mechanisms how IPA can ameliorate hepatic fibrosis.
Identifiants
pubmed: 34684510
pii: nu13103509
doi: 10.3390/nu13103509
pmc: PMC8538297
pii:
doi:
Substances chimiques
Indoles
0
RNA, Messenger
0
Transforming Growth Factor beta1
0
indolepropionic acid
830-96-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Finnish Diabetes Research Foundation
ID : 64808
Organisme : Kuopio university hospital project grant
ID : EVO/VTR grants 2005-2019
Organisme : Healh from science (TERVA)
ID : 404030
Organisme : Horizon 2020 Framework Programme
ID : MSCA, grant no. 740264
Organisme : NIH grant
ID : HL-095056, HL-28481, U01 DK105561
Organisme : Academy of Finland
ID : 321716, 138006, 324494, 316458
Organisme : ERA-NET NEURON 2019 translational biomarkers
ID : 334814
Références
Curr Biol. 2017 Nov 6;27(21):R1147-R1151
pubmed: 29112863
Gut Microbes. 2019;10(6):688-695
pubmed: 31030641
Sci Rep. 2017 Apr 11;7:46337
pubmed: 28397877
Front Med (Lausanne). 2021 Mar 22;8:648259
pubmed: 33829028
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Clin Biochem. 2015 Sep;48(13-14):923-30
pubmed: 26151226
Mol Nutr Food Res. 2020 Sep;64(17):e2000375
pubmed: 32738185
J Intern Med. 2019 Jul;286(1):32-40
pubmed: 30873652
Hepatol Commun. 2020 Nov 25;5(2):244-257
pubmed: 33553972
World J Gastroenterol. 2019 May 7;25(17):2019-2028
pubmed: 31114130
Diabetes Care. 2021 Sep;44(9):1970-1979
pubmed: 34253560
Cells. 2019 Nov 11;8(11):
pubmed: 31718044
PLoS One. 2016 Jun 29;11(6):e0158568
pubmed: 27355821
Liver Int. 2021 Apr;41(4):754-763
pubmed: 33219609
J Hepatol. 2012 Apr;56(4):952-64
pubmed: 22173168
Front Microbiol. 2020 Oct 27;11:575586
pubmed: 33193190
FASEB J. 2015 Mar;29(3):1043-55
pubmed: 25466902
Immunity. 2014 Aug 21;41(2):296-310
pubmed: 25065623
Front Biosci. 2002 Sep 01;7:d1899-914
pubmed: 12161342
Front Immunol. 2020 Apr 15;11:557
pubmed: 32351500
Nutrients. 2019 Jul 25;11(8):
pubmed: 31349604
Clin Nutr. 2019 Dec;38(6):2945-2948
pubmed: 30612852
Exp Mol Med. 2019 Sep 10;51(9):1-14
pubmed: 31506421
Nutr Diabetes. 2018 May 25;8(1):35
pubmed: 29795366
World J Gastroenterol. 2020 May 7;26(17):1993-2011
pubmed: 32536770
JHEP Rep. 2019 Jul 19;1(4):312-328
pubmed: 32039382
J Cell Biochem. 2001;81(3):507-13
pubmed: 11255233
Hepatology. 2020 Oct;72(4):1191-1203
pubmed: 31953865
Cell Metab. 2021 Feb 2;33(2):242-257
pubmed: 33232666
Neurogastroenterol Motil. 2018 Feb;30(2):
pubmed: 28782205
Nature. 2017 Nov 30;551(7682):648-652
pubmed: 29168502
Eur J Nutr. 2018 May;57(Suppl 1):1-14
pubmed: 29748817
J Lipid Res. 2014 Dec;55(12):2676-84
pubmed: 25344588
Gastroenterology. 2020 May;158(7):1881-1898
pubmed: 32044317
Nat Rev Gastroenterol Hepatol. 2017 Jul;14(7):397-411
pubmed: 28487545
Apoptosis. 2005 Oct;10(5):927-39
pubmed: 16151628
Am J Physiol Gastrointest Liver Physiol. 2015 May 15;308(10):G807-30
pubmed: 25767261
Hepatol Commun. 2019 Mar 01;3(4):456-470
pubmed: 30976737
J Neurosci Res. 2009 Jul;87(9):2126-37
pubmed: 19235887
Cancers (Basel). 2020 Aug 25;12(9):
pubmed: 32854297
Metabolites. 2020 May 01;10(5):
pubmed: 32369899
Gut. 2021 Apr;70(4):761-774
pubmed: 32694178
Arch Physiol Biochem. 2018 Oct;124(4):306-312
pubmed: 29113509
Metabolism. 2010 Jun;59(6):866-72
pubmed: 20015521
Diabetes Metab J. 2015 Oct;39(5):353-62
pubmed: 26566492
Am J Gastroenterol. 1999 Sep;94(9):2467-74
pubmed: 10484010
Nagoya J Med Sci. 2017 Nov;79(4):477-486
pubmed: 29238104
PLoS One. 2016 Apr 05;11(4):e0153118
pubmed: 27046197
Gut. 2021 Jun 14;:
pubmed: 34127525
J Vasc Surg. 2018 Nov;68(5):1552-1562.e7
pubmed: 29248242
Int J Obes (Lond). 2020 Apr;44(4):875-885
pubmed: 31388096
Cell Host Microbe. 2017 Jul 12;22(1):25-37.e6
pubmed: 28704649
J Mol Neurosci. 2002 Aug-Oct;19(1-2):213-7
pubmed: 12212784